Join Growin Stock Community!

Apimeds pharmaceuticals us, incAPUS.US Overview

US StockHealthcare
(No presentation for APUS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

APUS AI Insights

APUS Overall Performance

APUS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

APUS Recent Performance

-3.68%

Apimeds pharmaceuticals us, inc

0.05%

Avg of Sector

-0.31%

S&P500

APUS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

APUS Key Information

APUS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

APUS Profile

Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis. The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.

Price of APUS

APUS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

APUS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.10
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-0.41
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
2.10
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is APUS's latest earnings report released?

    The most recent financial report for Apimeds pharmaceuticals us, inc (APUS) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating APUS's short-term business performance and financial health. For the latest updates on APUS's earnings releases, visit this page regularly.

  • How much cash does APUS have?

    At the end of the period, Apimeds pharmaceuticals us, inc (APUS) held Total Cash and Cash Equivalents of 6.99M, accounting for 0.76 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is APUS's EPS continuing to grow?

    According to the past four quarterly reports, Apimeds pharmaceuticals us, inc (APUS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.14. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of APUS?

    Apimeds pharmaceuticals us, inc (APUS)'s Free Cash Flow (FCF) for the period is -1.75M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 836.36% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.